Zevra Therapeutics News and Activities

Zevra Therapeutics is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Zevra Therapeutics is a company listed under the stock ticker ZVRA (US).

They are in:

• Pharmaceuticals50%
• Biotechnology50%

View the org chart displaying its 33 main executives

Most searched biographies at Zevra Therapeutics

• Neil Mcfarlane, Chief Executive Officer and President
• Thomas Anderson, Director
• John Bode, Director

Popular executive movements at Zevra Therapeutics

• Justin Renz will join the company as Chief Financial Officer on Mar. 9, 2026  (posted on March 6 2026).
• Alicia Secor has joined the company as Director  (posted on December 2 2025).
• Wendy Dixon, Director, has left the company  (posted on December 2 2025).

Click here to view some more movements at Zevra Therapeutics

Create your alert
to follow the executive moves at Zevra Therapeutics.

Zevra Therapeutics has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).

Popular M&A news in Pharmaceuticals

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
• Hims & Hers has acquired Eucalyptus (posted on June 2 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Robert Ford - Chief Executive Officer and Chairman of the Board at Abbott
• Jonathan Leff - Director at Larimar Therapeutics

Learn more about the Pharmaceuticals industry

Press releases by Zevra Therapeutics

• KemPharm to Report Second Quarter 2022 Financial Results | KemPharm
• KemPharm to Present at the Canaccord Genuity 42nd Annual Growth Conference | KemPharm
• KemPharm to Participate in the 2022 Joint NNPDF-INPDA Conference and Meeting | KemPharm
• KemPharm Announces Research Affirming Serdexmethylphenidate’s Lower Potential for Abuse Featured in Peer-Reviewed Publication, Current Medical Research & Opinion | KemPharm
• Press Releases | KemPharm
• KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline | KemPharm
• KemPharm Reports First Quarter 2022 Financial Results and Corporate Updates | KemPharm
• Press Releases | KemPharm
• KemPharm to Present at Multiple Upcoming Investor Conferences | KemPharm
• KemPharm Announces Submission of Investigational New Drug Application for Phase 2 Trial of KP1077 in Idiopathic Hypersomnia (IH) | KemPharm
• View more press releases Close

Social media about Zevra Therapeutics

• Zevra Therapeutics on Wikipedia, Google News & Yahoo Finance
• Zevra Therapeutics on LinkedIn, X (Twitter) & YouTube